EUR/USD
1.04769
0.089%
Gold
2935.45
-0.583%
Oil
70.969
0.213%
USD/JPY
149.783
0.037%
GBP/USD
1.26351
0.090%
GBP/JPY
189.255
0.149%
Real-time News
The head of Japans steel industry: As global protectionism grows, Japan should consider its trade policy from a new perspective.An executive at U.S. medical technology company Medtronic: (On the issue of U.S. tariffs) We are looking for ways to optimize our manufacturing layout.On February 25, people familiar with the matter said that Indonesia and Apple (AAPL.O) have reached an agreement to lift the countrys ban on iPhone16, paving the way for an end to a five-month tug-of-war that forced Apple to increase its promised investment in Indonesia to $1 billion. The Indonesian Ministry of Industry, which is responsible for maintaining the ban, will sign an agreement with Apple as early as this week. The two sides will also hold a press conference, and the Indonesian Ministry of Industry plans to issue a license allowing the sale of iPhone16 as soon as possible. People familiar with the matter added that in addition to the $1 billion investment, Apple will also be committed to training locals to work in the research and development of Apple products so that they can develop similar software and design their own products. The move is intended to appease the government, which has been pushing Apple to establish research and development facilities in the country. However, although both parties agreed to the terms of lifting the ban, Indonesia has previously reneged and the agreement may still fall through.On February 25, the DeepSeek API open platform showed that DeepSeek has reopened API recharge. The deepseek-chat model discount period has ended, and the call price has been changed to 2 yuan per million input tokens and 8 yuan per million output tokens. DeepSeek had previously stopped recharges due to resource constraints.On February 25, Morgan Stanley published a research report stating that due to the continued sales pressure of traditional drugs, it decided to further reduce the sales forecast of Shijiazhuang Pharmaceutical Group (01093.HK) by 2.1% in 2024; the sales forecast for 2025 was raised by 3.5%; and the sales forecast for 2026 was raised by 2.7%. Morgan Stanley mentioned that since Shijiazhuang Pharmaceutical attaches great importance to research and development, it has raised its forecast for its research and development expenses, which is partially offset by lower sales expenses. The bank adjusted its profit forecasts for fiscal years 2024 to 2026 by -14%, +10% and -4.3%, respectively. In addition, the bank lowered its capital expenditure forecast for Shijiazhuang Pharmaceutical in the next few years to 7% per year (originally 9%), and slightly raised its target price from HK$6.6 to HK$6.8, giving it an overweight rating.
